Margin operasi Codexis Inc (CDXS)

Codexis Bio (CDXS) - logo korporat

Codexis, Inc. (CDXS) leads in enzyme development, advancing ECO Synthesis for RNA therapeutics and green chemistry. The operating margin spread confirms the effectiveness of this strategy, where the indicator value reaches -14.40. The business relies on the sale of consumables and licenses, generating stable FCF. Stability is ensured by a strong staff of protein engineers retained through equity options.

CDXS - Rentabilitas dodolan miturut bathi operasi Codexis Bio ing rentang 04.07.2022 - 19.11.2026

Rincian analitis perusahaan Codexis Bio (CDXS)

- rega saham lan konsensus proyeksi valuasi:
- rincian kapitalisasi pasar:
Analisis umum perusahaan:codexis.com, CDXS
Produk dadi Codexis Inc

Leveraging the CodeEvolver platform and inelastic demand for catalysts, Codexis, Inc. (CDXS) effectively monetizes its technological uniqueness. This operating margin quantifies the efficiency of converting revenue into earnings before interest and taxes. The metric measures the internal efficiency of the business model, excluding the impact of financial leverage. Growth in this indicator confirms the issuer's pricing power. Analyzing the operating margin helps avoid overpaying at local extremes.

Pesaing utama

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi